-$0.38 EPS Expected for NightHawk Biosciences (NYSE:NHWK) This Quarter

Wall Street brokerages expect that NightHawk Biosciences (NYSE:NHWK – Get Rating) will report earnings per share of ($0.38) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for NightHawk Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.42) and the highest estimate coming in at ($0.33). NightHawk Biosciences posted earnings per share of ($0.26) in the same quarter last year, which suggests a negative year over year growth rate of 46.2%. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that NightHawk Biosciences will report full year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.73) to ($1.29). For the next year, analysts expect that the business will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.32) to ($1.23). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow NightHawk Biosciences.

NightHawk Biosciences (NYSE:NHWK – Get Rating) last released its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.09. NightHawk Biosciences had a negative net margin of 1,995.52% and a negative return on equity of 30.28%.

NHWK has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of NightHawk Biosciences in a report on Tuesday, March 15th. StockNews.com initiated coverage on shares of NightHawk Biosciences in a report on Thursday, March 31st. They issued a “sell” rating for the company. Finally, B. Riley lowered their target price on shares of NightHawk Biosciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 18th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $14.33.

NightHawk Biosciences stock opened at $2.53 on Friday. The firm has a 50-day moving average price of $2.51 and a 200-day moving average price of $2.96. The firm has a market capitalization of $64.89 million, a PE ratio of -1.78 and a beta of 0.45. NightHawk Biosciences has a 12-month low of $1.60 and a 12-month high of $10.85.

A number of hedge funds have recently bought and sold shares of NHWK. Wolverine Trading LLC purchased a new position in NightHawk Biosciences in the 4th quarter worth about $33,000. Walleye Trading LLC purchased a new position in NightHawk Biosciences during the 4th quarter valued at about $55,000. Walleye Capital LLC purchased a new position in NightHawk Biosciences during the 4th quarter valued at about $76,000. Cubist Systematic Strategies LLC purchased a new position in NightHawk Biosciences during the 4th quarter valued at about $82,000. Finally, Goldman Sachs Group Inc. increased its position in NightHawk Biosciences by 12.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 56,465 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 6,278 shares during the period. 18.12% of the stock is currently owned by institutional investors.

NightHawk Biosciences Company Profile (Get Rating)

Heat Biologics, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Featured Stories